ArticleMicrobiology spectrum2022
Antimicrobial Susceptibility Survey of Invasive Haemophilus influenzae in the United States in 2016.
Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Revisiting mutational resistance to ampicillin and cefotaxime in Haemophilus influenzae.Genome medicine · 2024Pooled it
- Synergistic biofilm formation by the coexistence of nontypeable Haemophilus influenzae and Moraxella catarrhalis reduces amoxicillin efficacy.BMC microbiology · 2026Article
- Surveillance of epidemiological characteristics and temporal trends in antimicrobial resistance of Haemophilus influenzae in pediatric lower respiratory tract infections (2021-2024).Scientific reports · 2026Article
- Antimicrobial resistance trends among dominant pathogens in six clinical departments of the Fourth Affiliated Hospital of Guangxi Medical University, 2020-2024.Frontiers in public health · 2026Article
- Genetic population structure of Haemophilus influenzae at local and global scales.Nature microbiology · 2025Article
- Characteristics of 241 invasive and non-invasive Haemophilus influenzae isolated from patients under 14 years old, Hebei Province, China.BMC infectious diseases · 2025Observational
- Underdosed and Underappreciated: Why Japanese Community-Acquired Pneumonia Outcomes With Ampicillin-Sulbactam May Not Translate Globally.Open forum infectious diseases · 2025Article
- Immunological efficiency ofIranian journal of microbiology · 2025Article
- Article
- Prevalence of piperacillin/tazobactam resistance in invasiveJAC-antimicrobial resistance · 2024Article
- Antibiotic Resistance ofAntibiotics (Basel, Switzerland) · 2023Article
- Antibiotic Susceptibility and Molecular Typing of InvasiveMicroorganisms · 2023Article
- Imipenem heteroresistance but not tolerance inFrontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibiotics are important for the treatment and prevention of invasive Haemophilus influenzae disease. Reduced susceptibility to clinically relevant drugs, except ampicillin, has been uncommon in the United States. Susceptibility of 700 invasive H. influenzae isolates, collected through population-based surveillance during 2016, was assessed for 15 antibiotics using broth microdilution, according to the CLSI guidelines; a subset of 104 isolates were also assessed for rifampin susceptibility using Etest. Genomes were sequenced to identify genes and mutations known to be associated with reduced susceptibility to clinically relevant drugs. A total of 508 (72.6%) had reduced susceptibility to at least one antibiotic and more than half of the isolates exhibited reduced susceptibility to only one (33.6%) or two (21.6%) antibiotic classes. All tested isolates were susceptible to rifampin, a chemoprophylaxis agent, and <1% (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.